ANIP Earnings Date: Nov 5, 2026 (Estimated) — ANI Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ANIP's next earnings date?
ANI Pharmaceuticals, Inc. (ANIP) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.18 on revenue of $280.3M.
How did ANIP do in its last earnings report?
In its most recent report on Aug 7, 2026 (Q2 2026), ANI Pharmaceuticals, Inc. posted EPS of $2.21 versus the $2.04 estimate, a beat of 13.9%. Revenue was $266.0M against a $260.1M estimate. The stock's 1-day post-earnings move was -5.3%.
How much does ANIP stock move after earnings?
ANIP beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Q2 2026 | 2.04 | 2.21 | +13.92% | $266.0M | ✅ Beat | -5.30% | -9.51% | -13.80% |
| 2026-05-08 | Q1 2026 | 1.23 | 2.05 | +66.67% | $237.5M | ✅ Beat | -2.44% | -5.16% | -4.50% |
| 2026-02-27 | Q4 2025 | 1.83 | 2.33 | +27.32% | $247.1M | ✅ Beat | -4.21% | -2.01% | -5.61% |
| 2025-11-07 | Q3 2025 | 1.61 | 2.04 | +26.71% | $227.8M | ✅ Beat | +0.22% | -6.29% | -9.85% |
| 2025-08-08 | Q2 2025 | 1.26 | 1.80 | +42.86% | $211.4M | ✅ Beat | +18.07% | +30.42% | +37.95% |
| 2025-05-09 | Q1 2025 | -0.06 | 1.70 | +2933.33% | $197.1M | ✅ Beat | -7.31% | -16.78% | -11.67% |
| 2025-02-28 | Q4 2024 | 0.29 | 1.63 | +462.07% | $190.6M | ✅ Beat | +13.39% | +11.85% | +23.87% |
| 2024-11-08 | Q3 2024 | 1.09 | 1.34 | +22.94% | $148.3M | ✅ Beat | +5.24% | +0.91% | -0.60% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $248.3M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Sales of rare disease pharmaceutical products | 54.7% | $135.8M | +30.7% | — | $69.0M | $104.0M | $118.5M |
| Total Sales of Generics and Other | 40.5% | $100.7M | +6.8% | — | $103.0M | $94.2M | $98.7M |
| Sales of Established Brands | 4.8% | $11.8M | -10.5% | — | $25.1M | $13.2M | $10.7M |
By region
Q4 FY24 · $190.6M total
| Segment | Share | Revenue | YoY | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 95.7% | $182.4M | — | $116.5M | $131.8M | — | $137.4M |
| Non-US | 4.3% | $8.2M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.